NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of an aggregate of 2,250,000 shares of its common stock. OMRIX is offering 1,500,000 shares, and certain selling stockholders are offering an aggregate of 750,000 shares. The underwriters will be granted a 30-day option to purchase an aggregate of up to an additional 337,500 shares of common to cover over-allotments, if any. OMRIX will not receive any proceeds from the sale of common stock by the selling stockholders.
